Publications

• Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.
  Blood Adv Volume: 9 Page(s): 417 - 424
  01/28/2025 Authors: Fatola A; Evans MD; Brown J; Davis E; Johnson A; Antun AG; Farland AM; Woods R; Metjian A; Park YA
• A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.
  Res Pract Thromb Haemost Volume: 8 Page(s): 102388
  03/01/2024 Authors: Abou-Ismail MY; Zhang C; Presson AP; Chaturvedi S; Antun AG; Farland AM; Woods R; Metjian A; Park YA; de Ridder G
• A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.
  Blood Adv Volume: 8 Page(s): 620 - 623
  02/13/2024 Authors: Abou-Ismail MY; Zhang C; Presson AP; Chaturvedi S; Antun AG; Farland AM; Woods R; Metjian A; Park YA; de Ridder G
• Race, rituximab, and relapse in TTP.
  Blood Volume: 140 Page(s): 1335 - 1344
  09/22/2022 Authors: Chaturvedi S; Antun AG; Farland AM; Woods R; Metjian A; Park YA; de Ridder G; Gibson B; Kasthuri RS; Liles DK
• Therapeutic plasma exchange for intractable pruritus secondary to primary sclerosing cholangitis.
  J Clin Apher Volume: 31 Page(s): 495 - 496
  10/01/2016 Authors: Gibson B; Williams LA; Marques MB; Pham HP
• Occult Metastases in Pelvic Lymphadenectomy Specimens From Patients With Urothelial Carcinoma of the Bladder.
  Urology Volume: 94 Page(s): 161 - 166
  08/01/2016 Authors: Gordetsky J; Gibson B; Stevens TM; Ellenburg JL; Grizzle W; Rais-Bahrami S